Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #58

Submission information
Submission Number: 58
Submission ID: 150485
Submission UUID: 23993711-100d-4651-8a73-25592ea841e0

Created: Mon, 09/01/2025 - 15:57
Completed: Mon, 09/01/2025 - 16:02
Changed: Mon, 09/01/2025 - 16:02

Remote IP address: 10.208.24.230
Submitted by: Anonymous
Language: English

Is draft: No
Abstract Submission for Poster Presentation
Next-generation cancer models for pediatric solid cancer.
The Human Cancer Models Initiative (HCMI) is a global initiative founded by the National Cancer Institute (NCI), Cancer Research UK, Wellcome Sanger Institute, and the foundation Hubrecht Organoid Technology. The mission is to generate patient-derived Next-generation Cancer Models (NGCMs) from diverse tumor types, including rare adult and pediatric cancers, as a community resource. Unlike traditional cancer models, NGCMs are cultured under optimized conditions that better preserve the characteristics of the parental tumors. This preservation is validated through molecular and phenotypic analyses of tumor tissue and models, which are shared with the community alongside standard operating procedures (SOPs), informed consent templates, and clinical data case report forms (CRFs).
The Stanford University Cancer Model Development Center (referred to as STAN CMDCs) is one of several CMDCs that ensure the integrity and quality of this initiative. STAN CMDC is dedicated to pediatric solid tumors, emphasizing central nervous system (CNS) tumors, the leading cause of cancer-related death in children. We developed a standardized bioprocessing pipeline which yielded a functional tumor bank, achieving a 60-70% success rate in establishing NGCMs for long-term passaging. We have successfully generated and submitted 85 NGCMs along with case-associated clinical and biospecimen data, as well as internal QC data validating the derived cancer models.
These models partially capture the heterogeneity of pediatric CNS tumors, neuroblastoma, hepatoblastoma, Wilms tumor, and brain metastases from neuroblastoma and rare sarcoma-related cancers. Longitudinal biobanking has identified and characterized novel onco-fusion proteins, rare tumor entities, and recurrences, thereby enhancing therapeutic efficacy and promoting personalized treatment strategies.

{Empty}
  1. First Name: Emon
    Last Name: Nasajpour
    Organization: Stanford University
  2. First Name: Dena
    Last Name: Panovska
    Organization: Stanford University
  3. First Name: Ruolun
    Last Name: Wei
    Organization: Stanford University
  4. First Name: Conrado
    Last Name: Soria
    Organization: Frederick National Laboratory for Cancer Research
  5. First Name: Eva
    Last Name: Tonsing-Carter
    Organization: National Cancer Institute
  6. First Name: Julyann
    Last Name: Perez-Mayoral
    Organization: National Cancer Institute
  7. First Name: Louis
    Last Name: Staudt
    Organization: National Cancer Institute
  8. First Name: Calvin
    Last Name: Kuo
    Organization: Stanford University
  9. First Name: Daniela
    Last Name: Gerhard
    Organization: National Cancer Institute
  10. First Name: Melissa
    Last Name: Porter
    Organization: National Cancer Institute
  11. First Name: Rachana
    Last Name: Agarwal
    Organization: Frederick National Laboratory for Cancer Research
  12. First Name: Claudia
    Middle Initial: K
    Last Name: Petritsch
    Organization: Stanford University
Claudia K Petritsch
Stanford University